24.6 C
New York
Sunday, June 14, 2026

Tag: virus

newssourceFORcompanyinformationcontent1marketreleases

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Huawei Unveils Fully-Upgraded Xinghe Intelligent Network Offerings to Accelerate Digital and Intelligent Transformation in Asia Pacific

HONG KONG, June 11, 2025 /PRNewswire/ -- At Huawei Network Summit 2025 (Asia Pacific), Huawei unveiled fully-upgraded Xinghe Intelligent Network products and solutions for the...

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe,...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory...

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches...

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Communiqué de presse : Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de...

Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVirus

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers